CN
DNA Encoded Library

WuXi DEL Technology Service

Instant Access to Billion of Compounds at Affordable Price

WuXi DEL Technology Service provides customers with a cutting-edge hit identification and optimization platform using an affinity-based selection method against DNA-Encoded small molecule libraries. With operations in China, Europe and North America, clients range from small biotechnology companies to large pharmaceutical companies.
    • More than 90 billion synthetic compounds and growing.
    • International expert team located in North America, Asia and Europe.
    • Bioinformatics system to collect, process and analyze data and facilitate involvement of the client to make collective decisions.
    • Proven success with nano-molar hits in various target classes.
    • Flexible business model to accommodate different needs.
         

DELopen

DNA Encoded Library (DEL) Platform Offering More Than 2.8 Billion Compounds

DELopen is a platform initiated by WuXi AppTec Co. LTD and academia / institutions dedicated to the development and application of DNA Encoded Library (DEL) Technology. The goal of the platform is to provide free access of DEL libraries owned by participating partners to academic users for research in drug discovery. We envision that the new platform provides full protection of intellectual properties for both user and technology provider and will unlock the true potential of DEL technology.        

DELight

DNA Encoded Library (DEL) Service Package

DELight is WuXi DEL’s self-serve product that gives researchers direct access to a collection of more than eight billion compounds. Through the DELight service package, WuXi will provide a DNA Encoded Library kit and a user manual/protocols document to the research organization. Upon receipt of the kit, the researcher will perform affinity selection according to the protocol and return the sample to WuXi. WuXi then completes analysis such as PCR amplification, qPCR determination, purification and NGS (Next Generation Sequencing). A summary report (excluding structural and DNA sequence information) will be provided back to the researcher, who will make informed decision on follow up actions based on the selection results.